| 1. |
|
|
| 2. |
|
|
| 3. |
- Eriksson, Staffan
(författare)
-
Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker
- 2009
-
Ingår i: European Journal of Cancer Prevention. - 0959-8278 .- 1473-5709. ; 18, s. 220-224
-
Tidskriftsartikel (refereegranskat)abstract
- It is known that the concentration and activity of the DNA precursor enzyme thymidine kinase 1 (TK1) in serum is significantly elevated in patients with malignancies, as compared with levels in patients with benign tumours and those in healthy individuals. For the first time, the use of serum TK1 as a prognostic marker for patients with renal cell carcinoma (RCC) was examined. Serum TK1 protein (STK1p) concentration and serum TK1 activity (STK1a) were determined by a dot blot chemoluminescence assay and a radio enzyme assay, respectively. There was no correlation between STK1p and STK1a in the same sera from 27 RCC patients. Only one STK1p value as compared with 15 STK1a values was clearly above the cut-off values (2 pmol/l and 6 U/l, respectively) for healthy individuals. STK1a values did not correlate with the level of TK1 expression in tumour sections from the RCC patients, estimated by immunohistochemistry staining. However, there was a significant correlation between STK1a levels and the grade, stage and size of the RCC tumours. The discrepancy between the STK1p and the STK1a results is likely to be because of reduced ability of the TK1 antibody to recognize the STK1 in sera from RCC patients. We conclude that the activity of STK1 is a useful tool for evaluating the prognosis of patients with RCC. European Journal of Cancer Prevention 18:220-224 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
|
|
| 4. |
|
|
| 5. |
- Hemminki, K, et al.
(författare)
-
Lifestyle and cancer: effect of parental divorce
- 2006
-
Ingår i: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). - : Ovid Technologies (Wolters Kluwer Health). - 0959-8278. ; 15:6, s. 524-530
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
|
|
| 7. |
- Hernes, Eivor, et al.
(författare)
-
High prostate cancer mortality in Norway evaluated by automated classification of medical entities.
- 2008
-
Ingår i: European Journal of Cancer Prevention. - 0959-8278 .- 1473-5709. ; 17:4, s. 331-335
-
Tidskriftsartikel (refereegranskat)abstract
- The new standard of cause of death classification is an automated selection of the underlying cause of death using the international software Automated Classification of Medical Entities (ACME). Norwegian mortality rates are, however, based on manual classification of deaths. The aim of this study was to investigate how the use of ACME would influence Norwegian prostate cancer mortality rates. A previously described cohort of Norwegian prostate cancer patients deceased during 1996 was applied. Multiple causes of death data based on information from death certificates, autopsies and queries was coded according to ACME specifications, thereby ACME selected the underlying cause of death. In addition, the underlying cause of death that originally was manually classified for the official mortality statistics was retrieved from Statistics Norway in all cases. Age-standardized prostate cancer mortality rates (world population) per 100,000 person-years were calculated. A total of 2012 cases were included. On the basis of ACME classification, the age-standardized prostate cancer mortality rate in Norway for 1996 would have been 24.4 (95% confidence interval: 22.9-26.0) as compared with the rate based on manual classification for the official mortality statistics of 24.9 (95% confidence interval: 23.4-26.5). Thus, automated classification by ACME does not significantly influence the age-adjusted Norwegian prostate cancer mortality rate for the year 1996. There is reason to assume that the use of manual classification of deaths is not a major explanation of the high prostate cancer mortality rates in Norway.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
